Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Biologics 2020 Resources

Find information about our functional bioassays for biologic drug discovery and view scientific presentations and posters with the latest technology and data to help with your research needs.

Scientific Presentations


Bioluminescent Bioassays: From Reporter Cell Lines to Primary Cells

Presented by Jey Cheng, Sr Research Scientist, Promega Corporation

This presentation introduces our portfolio expansion into primary cell-based assays for immunotherapeutic drug development. You will learn about:

  • Using HiBiT-based target cells for ADCC and TDCC assays
  • NanoBiT immunoassays for measuring cytokine release 
Download PDF


New Bioluminescent Tools for the Development of TCR-Redirected Therapies

Presented by Julia Gilden, Sr Research Scientist, Promega Corporation

This presentation will discuss new bioluminescent tools to expedite the development of T cell-redirecting cancer therapies. You will learn about:

  • NanoBiT-based assay platforms that can quantitatively measure the potency of CD3 bispecific antibodies or BiTEs to induce T cell-dependent target cell killing and cytokine production.
  • TCRαβ-null reporter cell lines that can be used to screen transgenic TCRs against specific tumor antigen targets. 
Download PDF

Scientific Posters


Developing a Bioluminescent PBMC ADCC Assay for the Discovery and Characterization of Therapeutic Antibodies
Presented by Jey Cheng, Sr. Research Scientist

Download PDF

jamison-grailer-125 Cell-Based Reporter Bioassays for Development of Fc-Functional and Fc-Silent SIRPa/CD47 Checkpoint Inhibitors

Presented by Jamison Grailer, Sr Research Scientist

Download PDF

jeff-nelson-125x125 A No-Wash, Rapid FcRn Binding Immunoassay to Guide the Design and Development of Antibody Therapeutics

Presented by Jeff Nelson, Product Manager

Download PDF


Quantitative Cell-Based Bioassays to Advance Immunotherapy Programs Targeting Immune Checkpoint Receptors
Presented by Jamison Grailer, Sr Research Scientist

Download PDF

richard moravec Reproducible, MoA-Reflecting Reporter-Based Bioassays to Enable Drug Development of Biosimilars and Biobetters

Presented by Richard Moravec, Sr Research Scientist

Download PDF

dan lazar Rapid and Sensitive Determination of Cytokine Release from Cells without Sample Transfer

Presented by Dan Lazar, Sr Research Scientist

Download PDF

New Products

Lumit™ Immunoassays

Replace conventional immunoassays, such as Western blots and ELISAs, with new Lumit™ Immunoassays. These assays offer direct luminescence measurement in cell culture, broad dynamic range, and can be completed in as little as 30 minutes.

Lumit™ Immunoassays are available for a range of applications, including protein phosphorylation and pathway analysis, FcRn binding, cytokine detection, metabolite research, and more. You can also build your own Lumit™ immunoassays with our labeling and detection kits.

Learn More

Lumit immunoassay principle

General principle of a Lumit™ Immunoassay. Antibodies are chemically labeled with the small and large subunits of NanoLuc® Luciferase, known as SmBiT and LgBiT, respectively. In the presence of an analyte, the two antibodies come into close proximity, allowing SmBiT and LgBiT to form an active enzyme and generate a bright luminescence signal.